Posted by Michael Wonder on 30 Aug 2023
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies
30 August 2023 - As global drug development re-equilibrates following the COVID-19 pandemic, the number of new oncology drugs approved by leading regulatory authorities has increased.
In 2022, the UK's regulatory authority—the MHRA—granted new market authorisations to 11 new cancer therapies and more than ten supplemental (label extension) indications.
